The spokesperson said Wojcicki still intended to take 23andMe private. If you enjoyed this story, be sure to follow Business Insider on Microsoft Start.

23andMe Holding Co. has launched a new polygenic risk score (PRS) report for osteoporosis, available to 23andMe+ Premium members. This report assesses an individual's genetic likelihood of ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering ...

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human ...

23andMe is in need of cash and weighing a sale of the company. The DNA-testing company said Tuesday that it is exploring strategic alternatives, including a business combination and the sale of ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...